Aryastha's Bio Solutions ®

Aryastha Life sciences specializes in drug discovery and development services, harnessing the power of established cell line, primary cells from diseased organs, and in vivo models, including syngeneic and cell/tissue-derived systems. Our seamless integration of in vitro biology, in vivo pharmacology, and Drug Metabolism and Pharmacokinetics (DMPK) services offers robust support for drug discovery and early development endeavors. This integration and our expertise in discovery chemistry, CMC, and safety assessment enable us to successfully generate preclinical candidates and deliver comprehensive IND packages.
Get in Touch

Established Cell Lines

We use established cell lines from ATCC or other reputed organizations. These lines are very early passages free from common contamination like microplasma. This is mainly used for understanding the molecular pathway perturbation using developmental molecules in a high-throughput manner.
Get in Touch
Drug Discovery and Development Services
Medicinal Chemistry and Drug Discovery

Primary cell lines

These cells are mainly derived from diseased tissues (rodents and humans). These cells provide more biologically relevant data than that established cell lines. At Aryastha, we have developed a faster way to generate primary cells of our interest, and these cells can be used in various applications, from basic research to drug discovery. These lines are combined with 3D cell culture technologies for better reagents/models to improve research. These cells are ethically sourced and authenticated by testing possible contamination and key disease-specific markers.
Here are disease indications of different species (mice and humans) for our primary cell’s capabilities. Tumor cells (Breast, Lungs, GBM, CRC, HNSCC, Ovarian, etc.), Immune Cells (microphases, dendritic cells), Heart, Liver, and Kidney Cells.
Get in Touch

In Vivo Models

We have generated and developed primary cells-derived mouse models for oncology and non-oncology drug discovery- for efficacy, pharmacodynamic, and biomarker studies. We also use established cell lines derive murine model for PK/PD/Efficacy correlation. We have also developed syngeneic mouse models for drug discovery and development where both tumor/immune microenvironments are preserved.
We offer different in vitro and in vivo models mimicking the biology of human/rodent diseases. We use them to understand the biology, pathway perturbation, PK, and its correlation with target inhibition, efficacy, and meaningful understanding of possible biomarkers.
Get in Touch
Medicinal Chemistry and Drug Discovery

Aryastha's Bio Capabilities

Target-based Screening
Platforms

  • Kinase screening: Motility shift assay (EZ reader), Ulight, HTRF, IMAP, FP, ADP-Glo; LC/MS/MS, cellular phospho-substrate detection, NanoBRET

  • Other enzyme screening: IMAP, FP, FI (Fluorescence intensity), Colorimetric, LC-MS/MS

  • Coupling assay, cellular target engagement assay

  • (LC-MS/MS)

  • cAMP detection by LANCE ultra or HTRF

  • Calcium flux by FLIPR

  • IP3 detection

  • ß-arrestin internalization

  • Protein phosphorylation

  • Reporter gene-based readout

  • Cellular Tag-lite binding

  • Cellular PPI methods, SPA

  • Ternary Complex formation by NanoBRET

  • Biophysics screening: Biacore, BLI, Thermo-shift assay, TR-FRET, AlphaScreen

  • Protein characterization via SPR, LC-MS, thermo shift assay (TSA)

  • Screening by SPR-, LC-MS-, and/or TSA

Drug Development Services
Drug Development Services

Phenotypic-based Screening Platforms

Phenotypic-based screening platforms can serve as primary or secondary screening to guide SAR/SPR (Structure Activity /Property Relationships) in integrated or standalone collaboration modes.

  • Cancer cell panel screening

  • Cell proliferation (CellTiter Glo)

  • Long-term incubation studies

  • 3D culture assay

  • Apoptosis assay

  • Cell cycle analysis

  • Angiogenesis

  • Migration/invasion assay

  • Nuclear translocation assay

  • Target validation (shRNA, RNAi, Crispr-Cas9)

  • Characterization of cell/animal model (whole exome; RNAseq)

  • Cytokine/chemokine profiling

  • T cell activation/proliferation

  • MLR (i.e., human DC and T cells, mouse DC and T cells, etc.)

  • B cell activation  

  • NK cell activation

  • ADCC

  • Co-culture (i.e., immune cells with tumor cells)

  • PBMC assays

  • Human whole blood assays

  • PD1/PD-L1 binding and cell-based assays

  • Checkpoint binding and cellular assay 

  • Immune reporter cells or HEK293-derived reporter cells

  • Engineered cell line for CDX model study 

  • Signal pathway assay (i.e., JAK/STAT pathway, Sting pathway, RIG-I, IL6, TGFβ, etc.)

  • GSIS (Intact islet/pancreatic beta cell)

  • Fatty acid synthesis assay

  • Fatty acid oxidation assay 

  • TCA cycle assay

  • Glucose uptake

  • TG, glycogen, ketone body detection

In vitro Safety Pharmacology Screening

Safety pharmacology screening focuses on early hazard identification and subsequent compound profiling to guide preclinical in vivo and clinical safety studies.

  • Over 100 kinases

  • IC50 determination

  • Kinases: full-length or catalytic domain

  • Wild type and mutated versions

  • Multiple readouts (ADP-Glo, Lantha, etc.)

  • Multiple formats: calcium flux, cAMP, radioligand-based binding

  • A single dose or dose response for EC50 and IC50 determination

  • Selected targets relevant to clinical adverse drug reactions (ADR)

Integrated Drug Discovery Services

Therepeutic Areas

Our in vitro disease biology team works closely with our partners to evaluate targets, develop and validate assays, and design flexible workflows to meet project-specific goals. We have strong assay development expertise in key therapeutic areas
Integrated Drug Discovery Services

Oncology

Our oncology services offer advanced techniques including cancer cell panel screening, cell proliferation studies (CellTiter Glo), 3D culture assays, apoptosis analysis, and target validation (shRNA, RNAi, Crispr-Cas9). Additionally, we provide characterization of cell/animal models through whole exome and RNAseq analyses. Our comprehensive approach enables significant progress in cancer research.
Integrated Drug Discovery Services

Metabolic Disorder

In the realm of metabolic disorder research, our services encompass GSIS (Intact islet/pancreatic beta cell) assessments, fatty acid synthesis and oxidation assays, TCA cycle evaluations, glucose uptake studies, and the detection of TG, glycogen, and ketone bodies. Our comprehensive capabilities facilitate insightful discoveries in the field of metabolic disorders.
Integrated Drug Discovery Services

Immunology

Our immunology services encompass diverse techniques, including cytokine/chemokine profiling, T cell activation/proliferation, B cell and NK cell activation, ADCC, and immune cell co-culture with tumor cells. We specialize in PD1/PD-L1 binding assays, immune checkpoint evaluations, and immune reporter cells. Our offerings extend to engineered cel

Contact Us

India

Aryastha Life Sciences Private Limited, ARx,
Synergy Square II, Genome Valley, Shameerpet, Hyderabad,
500078, India

+91 91547 82433

USA

Aryastha Life Sciences, Inc.
One Broadway, 14th Floor
Cambridge, MA 02142

[email protected]

About Us

Services

Company

Social

© 2023 Aryastha Life Sciences | All Rights Reserved